Literature DB >> 27793335

Role of heterogeneous cell population on modulation of dendritic cell phenotype and activation of CD8 T cells for use in cell-based immunotherapies.

Hannah Frizzell1, Jaehyung Park1, Natacha Comandante Lou1, Kim A Woodrow2.   

Abstract

Dendritic cell (DC)-based immunotherapies have much utility in their ability to prime antigen-specific adaptive immune responses. However, there does not yet exist a consensus standard to how DCs should be primed. In this study, we aimed to determine the role of heterogeneous co-cultures, composed of both CD11c+ (DCs) and CD11c- cells, in combination with monophosphoryl lipid A (MPLA) stimulation on DC phenotype and function. Upon DC priming in different co-culture ratios, we observed reduced expression of MHCII and CD86 and increased antigen uptake among CD11c+ cells in a CD11c- dependent manner. DCs from all culture conditions were induced to mature by MPLA treatment, as determined by secretion of pro-inflammatory cytokines IL-12 and TNF-α. Antigen-specific stimulation of CD4+ T cells was not modulated by co-culture composition, in terms of proliferation nor levels of IFN-γ. However, the presence of CD11c- cells enhanced cross-presentation to CD8+ T cells compared to purified CD11c+ cells, resulting in increased cell proliferation along with higher IFN-γ production. These findings demonstrate the impact of cell populations present during DC priming, and point to the use of heterogeneous cultures of DCs and innate immune cells to enhance cell-mediated immunity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow; Cell activation; Dendritic cells; Immunotherapy; Priming protocol; T cells; Toll-like receptors (TLRs)

Mesh:

Substances:

Year:  2016        PMID: 27793335      PMCID: PMC5283719          DOI: 10.1016/j.cellimm.2016.10.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  48 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

Review 3.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

Review 4.  Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.

Authors:  A Reschner; P Hubert; P Delvenne; J Boniver; N Jacobs
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 5.  Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance.

Authors:  Maria Rescigno; Uri Lopatin; Marcello Chieppa
Journal:  Curr Opin Immunol       Date:  2008-10-22       Impact factor: 7.486

Review 6.  Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines.

Authors:  M Lienhard Schmitz; Axel Weber; Thomas Roxlau; Matthias Gaestel; Michael Kracht
Journal:  Biochim Biophys Acta       Date:  2011-07-20

Review 7.  Dendritic-cell-based therapeutic cancer vaccines.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

8.  Mycobacteria target DC-SIGN to suppress dendritic cell function.

Authors:  Teunis B H Geijtenbeek; Sandra J Van Vliet; Estella A Koppel; Marta Sanchez-Hernandez; Christine M J E Vandenbroucke-Grauls; Ben Appelmelk; Yvette Van Kooyk
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

Review 9.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03

Review 10.  Dendritic cells in cancer immunotherapy clinical trials: are we making progress?

Authors:  Lisa H Butterfield
Journal:  Front Immunol       Date:  2013-12-13       Impact factor: 7.561

View more
  1 in total

1.  Flt3-L enhances trans-epithelial migration and antigen presentation of dendritic cells adoptively transferred to genital mucosa.

Authors:  Jaehyung Park; Hannah Frizzell; Hangyu Zhang; Shijie Cao; Sean M Hughes; Florian Hladik; David M Koelle; Kim A Woodrow
Journal:  J Control Release       Date:  2020-10-06       Impact factor: 11.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.